Key result
Terazosin significantly improved peak and mean uroflow rates by 50% and 46%, and total symptom scores by 54% in males with symptomatic BPH (P<0.001).
Why the study?
Does terazosin improve symptom scores and urinary flow rates in males with symptomatic BPH?
Does terazosin improve symptom scores and urinary flow rates in males with symptomatic BPH?
p-value: p=<0.001
Terazosin safely and effectively improves urinary flow rates and symptom scores in men with symptomatic BPH.
No takes yet. Share an insight, caveat, or question.
May support terazosin for BPH symptoms; leaves open confirmation in randomized trials.
Lepor et al. (1991) conducted a review in Symptomatic benign prostatic hyperplasia (BPH) (n=163). Terazosin was evaluated on Peak and mean uroflow rates and symptom scores (p=<0.001). Terazosin significantly improved peak and mean uroflow rates by 50% and 46%, and total symptom scores by 54% in males with symptomatic BPH (P<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: